News

The FDA previously declined to approve de novo classification in April 2019.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.

No devices performed better than polysomnography, but the researchers believe they warrant further testing.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jacqueline French, MD.

William Rosenfeld, MD, discusses the decreases his team observed in concomitant medication use with cenobamate in patients with focal seizures.

The ability of the ABC/2 method to correctly identify patients with an infarct volume below a pre-defined cut-point proved to be very high for various cut-points.

The assistant professor of neurology and anesthesiology at Harvard Medical School discussed the landscape of ALS treatments and his outlook on how the future might evolve.

Alicia Roth, PhD, provides a Q&A perspective on the science between 2 terrifying, sleep-related events.

The findings suggest and confirm previous studies that suggested plasma p-tau181 may be used as a measure to monitor Alzheimer disease progression in clinical practice and treatment trials.

Men were observed to derive benefit from a Greek Mediterranean diet and women were found to generally adhere more closely to diet interventions than men.

The CEO of Nile AI spoke to how the newly founded company plans to develop data science techniques to improve the optimization of epilepsy care and management.

The new American Academy of Sleep Medicine guidelines are the first to use the GRADE system of evaluating behavioral insomnia therapies.

The Pfizer candidate PF-06939926 has also received fast track, orphan drug, and rare pediatric disease designations from the FDA.

The director of the Montefiore Headache Center discussed the current landscape of migraine treatments.

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

Brain Scientific’s disposable EEG cap can be applied by any clinical staff member within 5 minutes.

Researchers found amyloid-β positron emission tomography imaging and dopamine transporter imaging to be useful in characterizing phenotypes of the neurodegenerative conditions.

The hATTR amyloidosis treatment demonstrated an encouraging safety and tolerability profile, with a new drug application submission expected to come this year.

The executive director of the Norman Fixel Institute for Neurological Diseases gave his call-to-action on how to change the approval system for neurologic devices for rare diseases.

The phase 4 study will use total score on the Hammersmith Infant Neurological Examination Section 2 motor milestones as the primary end point over a 2-year period.

There was no statistically significant difference between treatment-related adverse events in the SB623 stem cell and control groups.

The follow-up TRAILBLAZER-EXT and broader population TRAILBLAZER-ALZ 2 studies are currently ongoing.

The assistant professor of neurology and anesthesiology at Harvard Medical School detailed the future outlook of ezogabine and whether it may be studied again in patients with ALS.

Episode 5 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Steven Vernino, MD, PhD, of UT Southwestern Medical Center. [WATCH TIME: 4 minutes]